WebDoctor Encyclopedia

Lymphomas

Primary effusion lymphoma (PEL)

Primary effusion lymphoma (PEL) is a rare, aggressive B-cell lymphoma caused by the KSHV/HHV-8 virus. It grows in fluid around the lungs, heart or in the abdomen, mostly in people living with HIV, and is treated with HIV medicines and chemotherapy.

Medically reviewed Last reviewed October 17, 2026

What is primary effusion lymphoma?

Primary effusion lymphoma (PEL) is a rare, aggressive type of B-cell non-Hodgkin lymphoma. Unlike most lymphomas, it does not usually form a lump or enlarge the lymph nodes. Instead, the lymphoma cells grow in fluid that collects in the body’s cavities.

The cavities most often affected are the space around the lungs (pleural cavity), the abdomen (peritoneal cavity) and the sac around the heart (pericardium). A build-up of fluid in one of these spaces is called an effusion, which gives the disease its name.

PEL is always linked with a virus called Kaposi sarcoma herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8). It was first recognised in the mid-1990s in people with AIDS, when researchers found KSHV in lymphomas growing in body cavities (Cesarman et al., 1995; Nador et al., 1996).

Most people with PEL have HIV infection with a weakened immune system. A smaller number are older people without HIV, or people taking immune-suppressing medicines after an organ transplant.

The World Health Organization places PEL among the KSHV/HHV-8-associated B-cell lymphoid proliferations and lymphomas (Alaggio et al., 2022).

1. Key facts at a glance

Feature Details
Type of disease Aggressive large B-cell lymphoma linked with KSHV/HHV-8
How common Very rare; about 4% of HIV-associated lymphomas and under 1% of all lymphomas
Who is affected Mainly men living with HIV; also older people without HIV and transplant recipients
Main sites Fluid around the lungs, in the abdomen or around the heart
Key symptoms Breathlessness, swollen abdomen, fever, night sweats, weight loss
Other viruses Epstein-Barr virus (EBV) is also present in most HIV-related cases
Main treatment Antiretroviral therapy plus combination chemotherapy
Outlook Serious; median survival about 1-2 years, but some people achieve long remissions

2. Types of primary effusion lymphoma

Type Description
Classic PEL Lymphoma cells are found in fluid in one or more body cavities, with no solid mass
Extracavitary PEL A solid tumour, often in the gut, skin, lung or lymph nodes, made of the same cells and carrying KSHV
EBV-positive PEL Most HIV-related cases; the cells also contain Epstein-Barr virus
EBV-negative PEL More common in older people without HIV

Extracavitary PEL behaves in a similar way to classic PEL. Some people have both a mass and an effusion, or develop an effusion later (Guillet et al., 2016).

3. Causes and risk factors

The role of KSHV/HHV-8

KSHV is a herpesvirus that infects some B cells and stays in them for life. In most healthy people, the immune system keeps the virus under control. When immunity is weak, infected B cells can grow out of control and become lymphoma.

The virus carries genes that help infected cells survive and divide, including copies of human cell-cycle and signalling genes (Cesarman et al., 1996). KSHV is also the cause of Kaposi sarcoma and of a type of multicentric Castleman disease (MCD).

Who is at risk?

Risk factor Explanation
HIV infection The main risk factor, especially with a low CD4 count or uncontrolled virus
Previous Kaposi sarcoma Many people with PEL have, or have had, Kaposi sarcoma
KSHV-associated multicentric Castleman disease Can occur before, with or after PEL
Organ transplantation Immune-suppressing medicines reduce control of KSHV
Older age in areas where KSHV is common For example the Mediterranean region and parts of Africa
Male sex Most patients are men

How is KSHV spread?

KSHV is mostly spread through saliva. It can also pass through sexual contact, blood and organ transplants. The virus is far more common in some parts of the world, such as sub-Saharan Africa and the Mediterranean, than in northern Europe or North America.

Being infected with KSHV does not mean someone will develop PEL. The lymphoma is very rare even among people who carry the virus.

PEL itself is not contagious. It cannot be caught from someone who has it.

4. How does it look

On scans

Feature What doctors see
Effusion Fluid around one or both lungs, in the abdomen (ascites) or around the heart
No large mass Typically no solid tumour and no large lymph nodes in classic PEL
Thickened lining The lining of the chest or abdomen may look slightly thickened
Extracavitary PEL A solid mass, for example in the bowel wall, skin or lymph nodes
PET-CT The cavity lining and fluid may take up the tracer, showing active disease

A chest X-ray or CT scan often shows a pleural effusion. An ultrasound or echocardiogram can show fluid in the abdomen or around the heart.

The fluid

When doctors drain the fluid, it may look cloudy, yellow or blood-stained. Under the microscope, the fluid contains many large abnormal lymphocytes.

Under the microscope

Feature Description
Cell size Large cells with big nuclei and prominent nucleoli
Appearance Ranges from immunoblastic and plasmablastic to anaplastic
Usual B-cell markers Often absent: CD19, CD20 and CD79a are usually negative
Markers present CD45, CD30, CD38, CD138 and MUM1/IRF4
KSHV marker LANA-1 (HHV-8 latency-associated nuclear antigen) is positive in all cases and is essential for the diagnosis
EBV EBV-encoded RNA (EBER) is positive in most HIV-related cases

Because PEL cells lack the usual B-cell markers, the diagnosis can be difficult. Proving the presence of KSHV in the cells is the key step (Narkhede, Arora and Ujjani, 2018).

Visible signs

Others may notice a swollen abdomen, breathlessness on mild effort or weight loss. People who also have Kaposi sarcoma may have purple or brown patches on the skin or in the mouth.

5. Symptoms

Symptoms depend on which cavity is affected and how much fluid has built up.

Fluid around the lungs

  • Breathlessness, which gets worse over days or weeks
  • Dry cough
  • Chest discomfort or a feeling of tightness
  • Needing to sleep propped up

Fluid in the abdomen

  • Swelling of the abdomen and weight gain from fluid
  • Feeling full quickly after eating
  • Abdominal discomfort
  • Nausea and loss of appetite

Fluid around the heart

  • Breathlessness, especially when lying flat
  • Fast heartbeat and dizziness
  • Swollen legs
  • In severe cases, a dangerous drop in blood pressure (cardiac tamponade), which is an emergency

General symptoms

Symptom Notes
Fever Often without infection
Drenching night sweats Known as a “B symptom”
Weight loss More than 10% of body weight in six months
Tiredness Common and often severe

KSHV inflammatory cytokine syndrome (KICS)

Some people develop KICS, a condition in which KSHV drives very high levels of inflammatory signals such as interleukin-6. It causes high fevers, low blood counts, swelling and low blood pressure, and needs urgent treatment.

When to seek medical advice

See a doctor promptly for breathlessness that is getting worse, a swelling abdomen, or ongoing fever and night sweats, especially if you live with HIV.

Seek emergency help for severe breathlessness, chest pain or fainting.

6. Diagnosis

Test Purpose
Chest X-ray, ultrasound and CT Show where fluid has collected
Drainage of the fluid Relieves symptoms and provides cells for testing
Cytology and flow cytometry Identify large abnormal lymphocytes
Immunohistochemistry Shows CD30, CD138 and MUM1, and confirms LANA-1 positivity
EBV testing (EBER) Checks for Epstein-Barr virus in the cells
Biopsy Needed for extracavitary PEL or a thickened lining
PET-CT Shows the extent of disease
HIV test, CD4 count and HIV viral load Essential for every patient
KSHV viral load in blood Helps to assess disease activity and KICS
Blood tests Blood count, kidney and liver function, LDH, IL-6 and CRP
Bone marrow tests Sometimes done if blood counts are low

Conditions that can look similar

Condition How it differs
Pleural effusion from infection or heart failure No lymphoma cells in the fluid
Pleural mesothelioma A tumour of the lining cells, not lymphocytes
Plasmablastic lymphoma Similar cells, but KSHV-negative
Diffuse large B-cell lymphoma with an effusion Usually CD20-positive and KSHV-negative
Fluid overload-associated large B-cell lymphoma KSHV-negative; usually older people with heart, liver or kidney disease and a better outlook

7. Treatment

PEL is treated at a specialist lymphoma centre, ideally with an HIV specialist working alongside the haematology team. There is no single agreed standard, because the disease is so rare (Narkhede, Arora and Ujjani, 2018).

Main treatment parts

Treatment Role
Antiretroviral therapy (ART) Started or continued in everyone with HIV; restores immunity and improves survival
Combination chemotherapy CHOP or dose-adjusted EPOCH; given in cycles over several months
Drainage of fluid Repeated drainage or a long-term drain to ease breathlessness or swelling
Infection prevention Antibiotics and antivirals to prevent infections such as pneumocystis pneumonia
Reducing immune suppression In transplant recipients, if possible

Chemotherapy

CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) and dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) are the most commonly used regimens.

Rituximab usually adds little, because PEL cells normally lack CD20. It may be used when PEL occurs together with KSHV-associated multicentric Castleman disease or in rare CD20-positive cases.

Treatment of relapsed or resistant disease

Option Notes
Further chemotherapy Different drug combinations
High-dose chemotherapy with autologous stem cell transplant For selected people who respond well
Brentuximab vedotin Targets CD30, which PEL cells often carry; used in trials or off-label
Pomalidomide or lenalidomide Immune-modulating drugs studied in KSHV-associated diseases (Lurain et al., 2021)
Daratumumab Targets CD38; activity has been reported in refractory PEL (Shrestha et al., 2023)
Clinical trials Strongly encouraged

Side effects of treatment

Side effect Notes
Low blood counts and infections The main risk, especially with HIV
Hair loss Usually temporary
Nausea and tiredness Controlled with supportive medicines
Tingling in hands and feet From vincristine
Drug interactions Some HIV medicines interact with chemotherapy, so regimens are planned together

8. Outlook (prognosis)

PEL has historically had a poor outlook, with median survival of around 6 months in the early years after it was first described. Results have improved with effective antiretroviral therapy and modern chemotherapy.

Factor Effect on outlook
Good performance status Better outlook (Boulanger et al., 2005)
Taking effective ART Better outlook
Only one cavity involved Better outlook
Complete response to chemotherapy Better outlook; some people stay in remission for years
Several cavities involved Poorer outlook
KICS or multicentric Castleman disease Poorer outlook

In a French study of 51 people with HIV, the median survival was about 10 months. People who reached complete remission did much better (Guillet et al., 2016).

In a later study from the US National Cancer Institute, median survival was about 22 months. Survival levelled off after about two years, meaning that people who were well at that point often stayed in remission for a long time (Lurain et al., 2019). Treatment with the aim of long-term control is therefore offered to everyone who is fit enough.

9. Prevention

There is no vaccine against KSHV. The best ways to lower the risk of PEL are:

  • Testing for HIV and starting antiretroviral therapy early
  • Taking HIV medicines every day to keep the virus suppressed and the CD4 count healthy
  • Safer sex and not sharing needles
  • Careful monitoring of transplant recipients who carry KSHV

10. Living with primary effusion lymphoma

  • Take HIV medicines exactly as prescribed, including during chemotherapy
  • Report fever promptly, as infections can become serious quickly
  • Ask about a long-term drain if fluid keeps coming back
  • Eat well and stay active as much as possible
  • Seek emotional support; HIV and lymphoma charities offer advice and peer support
  • Keep a list of all medicines to help avoid drug interactions

11. Frequently asked questions

Question Answer
Is PEL the same as Kaposi sarcoma? No. Both are caused by KSHV, but PEL is a lymphoma and Kaposi sarcoma is a tumour of blood vessel cells
Can people without HIV get PEL? Yes, mainly older people in areas where KSHV is common and transplant recipients
Can PEL be cured? Some people achieve long-lasting remission, especially with ART and a complete response to chemotherapy
Why does the fluid come back? Lymphoma cells keep producing fluid until the lymphoma is controlled
Will I need to stop my HIV medicines? No. ART is continued; the team may change some drugs to avoid interactions
Is PEL inherited? No

12. Questions to ask your care team

  • Is the lymphoma classic or extracavitary PEL?
  • Which cavities are affected?
  • What chemotherapy do you recommend and why?
  • How will my HIV treatment be managed during chemotherapy?
  • Do I have signs of KICS, Kaposi sarcoma or Castleman disease?
  • What can be done if the fluid keeps coming back?
  • Are there clinical trials I could join?

Resources

  1. Alaggio, R. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms’, Leukemia, 36(7), pp. 1720-1748.
  2. Boulanger, E. et al. (2005) ‘Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS’, Journal of Clinical Oncology, 23(19), pp. 4372-4380.
  3. Cesarman, E. et al. (1995) ‘Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas’, New England Journal of Medicine, 332(18), pp. 1186-1191.
  4. Cesarman, E. et al. (1996) ‘Kaposi’s sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi’s sarcoma and malignant lymphoma’, Journal of Virology, 70(11), pp. 8218-8223.
  5. Guillet, S. et al. (2016) ‘Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution’, American Journal of Hematology, 91(2), pp. 233-237.
  6. Lurain, K. et al. (2019) ‘Viral, immunologic, and clinical features of primary effusion lymphoma’, Blood, 133(16), pp. 1753-1761.
  7. Lurain, K. et al. (2021) ‘Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma’, Journal for ImmunoTherapy of Cancer, 9(2), e002097.
  8. Nador, R.G. et al. (1996) ‘Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus’, Blood, 88(2), pp. 645-656.
  9. Narkhede, M., Arora, S. and Ujjani, C. (2018) ‘Primary effusion lymphoma: current perspectives’, OncoTargets and Therapy, 11, pp. 3747-3754.
  10. Shrestha, P. et al. (2023) ‘Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease’, OncoImmunology, 12(1), 2163784.
  11. National Cancer Institute (2026) AIDS-Related Lymphoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lymphoma/hp/aids-related-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.